Chemomab Therapeutics

Company Overview

Snapshot

Founded in November 2011 by Adi Mor, Chemomab Therapeutics operates with 11–50 employees. The company has raised a total of $90.5 million across 7 funding rounds from 12 investors. In July 2024, Chemomab Therapeutics closed a $10 million private placement, with participation from OrbiMed.

Business overview

Chemomab Therapeutics is a clinical-stage biotechnology company focused on discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet medical needs. The company's core technology revolves around CM-101, a first-in-class monoclonal antibody designed to neutralize CCL24 activity, a soluble protein playing a pivotal role in promoting fibrosis and inflammation. Chemomab serves the healthcare and life sciences industries, specifically targeting patients with severe and life-threatening conditions such as NASH and primary sclerosing cholangitis, operating within the pharmaceuticals and drug discovery and development sectors.

Strategic signal

Chemomab Therapeutics is demonstrating a clear strategic focus on advancing its lead candidate, CM-101, through clinical development. The company's consistent presentation of clinical data at major scientific conferences, including the upcoming AASLD The Liver Meeting® 2024 and 2025, highlights ongoing progress in its Phase 2 trial for primary sclerosing cholangitis. This sustained engagement with the scientific community and commitment to data dissemination signals a robust development pipeline and a proactive approach to validating its therapeutic approach for investors.

Company Intelligence Q&A

What was a significant recent financial event for Chemomab Therapeutics?

In July 2024, Chemomab Therapeutics announced the closing of a $10 million private placement. This funding round saw participation from investors including OrbiMed and Sphera Global Healthcare Fund.

What is the status of Chemomab Therapeutics' CM-101 clinical program for Primary Sclerosing Cholangitis?

Chemomab Therapeutics is conducting a global Phase 2 trial for CM-101 in primary sclerosing cholangitis patients, with top-line data readout targeted for the second half of 2024. The company plans to present positive Phase 2 clinical data in a distinguished plenary session at DDW 2025.

Has Chemomab Therapeutics received any special regulatory designations for CM-101?

In November 2023, Chemomab Therapeutics received FDA Fast Track Designation for CM-101 for the treatment of Primary Sclerosing Cholangitis, recognizing the potential to address an unmet medical need.

What was a key leadership appointment at Chemomab Therapeutics?

In September 2021, Chemomab Therapeutics announced the appointment of Dale Pfost as Chief Executive Officer, a strategic move to guide the company's continued development.

What was the nature of Chemomab Therapeutics' public listing?

Chemomab Therapeutics became public on NASDAQ in March 2021 through a reverse merger with Anchiano Therapeutics, marking a significant milestone in the company's growth and access to public markets.